Policy Developments - The National Health Commission and 13 other departments announced the "Five Health Promotion Action Plan" for children and adolescents, aiming to improve health in areas such as obesity, myopia, psychological behavior abnormalities, spinal deformities, and dental caries by 2026-2030 [2] Drug and Medical Device Approvals - Aosheng Pharmaceutical received approval for the market launch of the raw materials for Palbociclib and Dapagliflozin, which will enhance the company's product line and competitiveness [4] - Aied Biological obtained a medical device registration certificate for its BRCA1/BRCA2 gene mutation detection kit for prostate cancer, marking the first approval for this indication in China [5] Capital Markets - Yingsi Intelligent successfully listed on the Hong Kong Stock Exchange, raising a total of HKD 2.277 billion, becoming the first AI-driven biopharmaceutical company to list under the main board rules [7] - China Pharmaceutical announced a plan to acquire 70% of Shanghai Zezheng Pharmaceutical for RMB 525 million, focusing on improved drug development services [8] - Yuekang Pharmaceutical submitted an application for H-share issuance to the Hong Kong Stock Exchange [9] Industry Events - Guangdong Province will implement a "one registration for three days" policy in public medical institutions starting January 1, 2026, allowing patients to return for follow-up consultations without additional registration fees within three days [11] Company Developments - Jincheng Pharmaceutical signed a supplementary agreement regarding tax payment responsibilities with shareholders, clarifying compensation terms related to tax liabilities [12] - *ST Chang Pharmaceutical faced a court ruling rejecting its restructuring application, leading to the bankruptcy of its subsidiary and potential delisting risks due to financial misconduct investigations [14]
英矽智能上市首日大涨；法院裁定不予受理*ST长药重整申请